UBS AM
TBPH icon

UBS AM’s Theravance Biopharma TBPH Stock Holding History

UBS AM’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Sell
1,842
-17,599
-91% -$291K ﹤0.01% 3041
2026
Q1 		$316K Buy
19,441
+19,042
+4,772% +$337K ﹤0.01% 2651
2025
Q4 		$7.46K Buy
+399
New +$6.62K ﹤0.01% 2908
2025
Q1 		– Sell
-150,039
Closed -$1.41M – 2699
2024
Q4 		$1.41M Buy
150,039
+32,534
+28% +$296K ﹤0.01% 2212
2024
Q3 		$947K Sell
117,505
-21,372
-15% -$185K ﹤0.01% 2420
2024
Q2 		$1.18M Buy
138,877
+74,349
+115% +$671K ﹤0.01% 2291
2024
Q1 		$579K Hold
64,528
– – ﹤0.01% 2240
2023
Q4 		$725K Buy
64,528
+3,113
+5% +$31.3K ﹤0.01% 2189
2023
Q3 		$530K Hold
61,415
– – ﹤0.01% 2272
2023
Q2 		$666K Hold
61,415
– – ﹤0.01% 2202
2023
Q1 		$666K Sell
61,415
-3,624
-6% -$38.3K ﹤0.01% 2202
2022
Q4 		$730K Sell
65,039
-7,379
-10% -$77.6K ﹤0.01% 2009
2022
Q3 		$734K Hold
72,418
– – ﹤0.01% 2143
2022
Q2 		$656K Sell
72,418
-2,345
-3% -$21.6K ﹤0.01% 2171
2022
Q1 		$715K Buy
74,763
+609
+0.8% +$5.97K ﹤0.01% 2304
2021
Q4 		$819K Buy
74,154
+9,654
+15% +$84.1K ﹤0.01% 2313
2021
Q3 		$477K Buy
64,500
+579
+0.9% +$6.48K ﹤0.01% 2524
2021
Q2 		$928K Buy
63,921
+3,127
+5% +$58.7K ﹤0.01% 2253
2021
Q1 		$1.24M Hold
60,794
– – ﹤0.01% 1984
2020
Q4 		$1.08M Buy
60,794
+17,366
+40% +$312K ﹤0.01% 1945
2020
Q3 		$642K Hold
43,428
– – ﹤0.01% 2020
2020
Q2 		$912K Buy
43,428
+9,624
+28% +$247K ﹤0.01% 1849
2020
Q1 		$781K Buy
33,804
+47
+0.1% +$1.18K ﹤0.01% 1790
2019
Q4 		$874K Buy
33,757
+6,932
+26% +$135K ﹤0.01% 1977
2019
Q3 		$523K Buy
26,825
+13,696
+104% +$277K ﹤0.01% 2269
2019
Q2 		$214K Hold
13,129
– – ﹤0.01% 2519
2019
Q1 		$298K Sell
13,129
-7,248
-36% -$184K ﹤0.01% 2320
2018
Q4 		$521K Buy
20,377
+3,100
+18% +$83.7K ﹤0.01% 1978
2018
Q3 		$564K Buy
17,277
+8,158
+89% +$222K ﹤0.01% 2037
2018
Q2 		$207K Hold
9,119
– – ﹤0.01% 2464
2018
Q1 		$221K Sell
9,119
-7,958
-47% -$219K ﹤0.01% 2343
2017
Q4 		$476K Sell
17,077
-6,921
-29% -$205K ﹤0.01% 1996
2017
Q3 		$822K Buy
23,998
+3,172
+15% +$104K ﹤0.01% 1790
2017
Q2 		$830K Buy
20,826
+14,107
+210% +$542K ﹤0.01% 1732
2017
Q1 		$247K Hold
6,719
– – ﹤0.01% 2086
2016
Q4 		$214K Sell
6,719
-5,300
-44% -$164K ﹤0.01% 2093
2016
Q3 		$436K Hold
12,019
– – ﹤0.01% 2056
2016
Q2 		$273K Buy
+12,019
New +$260K ﹤0.01% 2269
2015
Q2 		– Sell
-471,712
Closed -$8.18M – 2721
2015
Q1 		$8.18M Buy
471,712
+237,900
+102% +$4.36M 0.01% 927
2014
Q4 		$3.49M Buy
233,812
+3,100
+1% +$54K ﹤0.01% 1135
2014
Q3 		$5.32M Buy
230,712
+9,800
+4% +$284K 0.01% 1021
2014
Q2 		$7.04M Buy
+220,912
New +$6.65M 0.01% 955

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

UBS AM's TBPH Position: Q2 2026 in Review

UBS AM reduced its Theravance Biopharma (TBPH) stake by 91% in Q2 2026, selling an estimated $291K and leaving 1,842 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3041.

UBS AM first reported a position in TBPH in Q2 2014 and has held it in 42 quarters since. The position peaked at $8.18M in Q1 2015. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • UBS AM held 1,842 shares of Theravance Biopharma worth $31.3K as of Q2 2026.
  • UBS AM sold 17,599 Theravance Biopharma shares in Q2 2026, an estimated $291K.
  • Theravance Biopharma made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3041 holding.
  • UBS AM first reported a position in Theravance Biopharma in Q2 2014 and has held it in 42 quarters since.
  • UBS AM's Theravance Biopharma position peaked at $8.18M in Q1 2015.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.